Steve Greenaway Director at Biomarker Consulting Ltd and Visiting Research Fellow at King’s College London.
Quintiles Drug Research Unit at Guy’s Hospital
Manager Biomarker Laboratory
February 2009 – August 2016
Responsible for the supervision of the Biomarker Laboratory’s Phase 1 studies. Expert sputum cytologist, tissue specialist and holder of the site’s Human Tissue License. Carried out numerous ex vivo assays, cell stimulations and biopsy processing. Including bronchial, adipose and striated muscle biopsies. Performed many sputum inductions and processed many samples using a variety of methods. Became the Principal Scientist of the Biospit Initiative harmonising sample processing in multi-centre Phase 2 studies, which involved determination of appropriate methods for the study, writing the Lab Manual and training materials followed by presenting at Investigator meetings and on-site training.
King’s College London
2000 – 2009
Responsible for the supervision of the Clinical Research Laboratory’s commercial studies. Expert sputum cytologist, Kings was often used as the central laboratory in respiratory studies as well as for training and protocol harmonisation. With specialisations in immunomagnetic (MACs and Dynabeads) cell separations from blood and other fluids, flow cytometry, proteomics, biopsy processing and RNA isolation at the laboratory level. Spirometry, sputum induction, assistance in bronchoscopy, taking blood via a cannula and exhaled breath condensate collection at the clinical level
Cardiff University School of Biosciences
Senior Research Associate
Carbury Herne Ltd
1990 – 1996
|Last Date Attended||Institution Name, Country||Education Level/Degree||Area of Study||Completion Status|
|07/1981||University of Birmingham, UK||MSc||Biotechnology||Completed|
|09/1980||Thames Polytechnic, UK||2(ii) BSc Hons||Applied Biology||Completed|
|07/1976||St Olave’s Grammar School for Boys, UK||GCSE A, AS and O levels||Zoology, Chemistry and Physics||Completed|
|12/2009||Quintiles Drug Research Unit, UK||Pass||GCP Update training||Completed|
|10/2000||King’s College London, UK||Pass||Basic and Advanced ICH GCP 2 day training course||Completed|
|11/2000||Beckton Dickinson Ltd, UK||Pass||FACs Calibur Training Course||Completed|
|02/2004||King’s College London, UK||Pass||U.K. Clinical Trail Legislation Day||Completed|
|11/2007||BMS Corporation, UK||Pass||Centralized Spirometry Certification||Completed|
|05/2008||European Respiratory Society, UK||Pass||ERS online six week spirometry course||Completed|
|2009-2016||Quintiles Drug Research Unit, UK||Pass||GCP Training||Completed|
|06/2008||King’s College London, UK||Pass||Venepuncture and Cannulation course||Completed|
Current Memberships in Professional Organizations
- European Respiratory Society (ERS)
Publications, Doctoral Thesis
- Singh D, Siew L,Cristensen J, Plumb J, Clarke GW, Greenaway S, Perros Huget, C, Clarke N, Kilty I, Tan L. Oral and inhaled p38 MAPK inhibitors: effects on inhaled LPS challenge in healthy subjects. Eur J Clin Parmacol 2015 Oct;71(10):1175-84.
- Patel N, Cunoosamy D, Hegelund Myrback T, Pehrson R, Taib Z, Jansson P, Lundin S, Greenaway SD, Clarke GW, Siew L. European Respiratory Journal 2015 46: OA483
- Clarke GW, Diamant Z, Greenaway S, Rainer M, Allen E, Gispert J. Launching the BIOSPIT Initiative: Harmonizing Sputum Outcomes in Multicenter Trials. Pulm Pharmacol Ther. 2013 Jan 2. pii: S1094-5539(12)00178-2. doi: 10.1016/j.pupt.2012.12.007. [Epub ahead of print]
- Clarke GW, Gill M, Greenaway SD Siew LQ. Inhaled models of Inflammation in asthma Phase I/II clinical trials. In press Journal of Clinical Investigation
- Clarke GW, Mitchell JA, Morgan, MW, Greenaway SD, Simcock DE, Greenough A, O’Connor BJ. Endogenous nitric oxide mediates increased airway mucosal blood flow associated with asthma. Submitted to JACI.
- Clarke GW, Greenaway SD, Allen EM, Wilbraham D, Mant TGK. Biomarkers of Inflammation In Asthma: Predicting The Late Asthmatic Response. Am J Respir Crit Care Med 181;2010:A2846
- Clarke GW, Sarton M, Greenaway SD, Vos TP, O’Connor BJ. Vascular endothelial growth factor (VEGF), a specific marker of angiogenesis, is increased in asthmatic airways following allergen challenge. ERJ 2004; 24 (suppl 48): A1500.
- Tan L, Christensen J, Bridger H, Clarke N, Kilty I, Perros-Huguet C, Yeadon M, Greenaway S, Pattwell C, Brown K, Plumb J, Jagger C, Siew L, Singh D.Effects Of Oral And Inhaled p38 Inhibitors On Sputum Inflammatory Markers Following Whole Lung Lipopolysaccharide (LPS) Challenge In Healthy Subjects. Am J Respir Crit Care Med 185;2012:A6795
- Greenaway SD, Blackwell S, Jhali N, Stenning J, Wilbraham D, Clarke GW. Variability of Airway Conductance (SGaw) in Healthy Volunteers Am J Respir Crit Care Med 181;2010:A5003
- Tan E, Jones I, Tweedy S, Siew L, Greenaway S, O’Connor B. The Novel Oral P38 Inhibitor, Ph-797804, Inhibits Inhaled Lipopolysaccharide (LPS)-Induced Airway And Systemic Inflammatory Markers In Healthy Subjects. Am J Respir Crit Care Med 183;2011:A2554
- Ying S, O’Connor BJ, Meng Q, Woodman N, Greenaway S, Wong H, Mallett K, Lee TH, Corrigan C Expression of prostaglandin E(2) receptor subtypes on cells in sputum from patients with asthma and controls: effect of allergen inhalational challenge. J Allergy Clin Immunol. 2004 Dec;114(6):1309-16.
Other Relevant Information
Relevant Non-Clinical Training
- Attended American Thoracic Society Congress in Denver USA, May 2011.
- Attended American Thoracic Society Congress in San Francisco USA, May 2012.
- Attended European Respiratory Society Conferences 2011, 2012, 2013 and 2016